Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
Launched by GALDERMA R&D · Apr 30, 2008
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
Same as above.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Subjects with a minimum of 20 inflammatory lesions on the face;
- • 2. Subjects with a minimum of 15 and a maximum of 100 non-inflammatory lesions (open and closed comedones) on the face, excluding the nose;
- • 3. Subject has a Global Severity Assessment
- Exclusion Criteria:
- • 1. Subjects with more than three nodulo-cystic lesions
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Portland, Oregon, United States
Sacramento, California, United States
Louisville, Kentucky, United States
Warren, Ohio, United States
Patients applied
Trial Officials
Ron W Gottschalk, MD
Study Director
Galderma R&D
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials